Literature DB >> 31807943

Does helping mothers in multigenerational ADHD also help children in the long run? 2-year follow-up from baseline of the AIMAC randomized controlled multicentre trial.

Julia M Geissler1, Timo D Vloet2, Nora Strom2, Charlotte Jaite3, Erika Graf4, Viola Kappel3, Andreas Warnke2, Christian Jacob5, Klaus Hennighausen6, Barbara Haack-Dees6, Katja Schneider-Momm6, Swantje Matthies7, Michael Rösler8, Wolfgang Retz8,9, Susann Hänig10, Alexander von Gontard10, Esther Sobanski11,12, Barbara Alm11, Sarah Hohmann13, Luise Poustka14, Michael Colla15, Laura Gentschow3, Christine M Freitag16, Alexander Häge13, Martin Holtmann17, Katja Becker13,18, Alexandra Philipsen7,19, Thomas Jans2.   

Abstract

ADHD often affects multiple generations in a family. Previous studies suggested that children with ADHD benefit less from therapy if parents are also affected, since ADHD symptoms interfere with treatment implementation. This two-group randomised controlled trial examined whether targeting maternal ADHD boosts the efficacy of parent-child training (PCT) for the child's ADHD. Here, we report follow-up results 2 years from baseline. Mothers of 144 mother-child dyads (ADHD according to DSM-IV) were examined for eligibility (T1) and randomised to 12 weeks of intensive multimodal treatment comprising pharmacotherapy and DBT-based cognitive behavioural group psychotherapy (TG, n = 77) or clinical management comprising non-specific counselling (CG, n = 67) for Step 1 (concluded by T2). Subsequently, all dyads participated in 12 weekly PCT sessions for Step 2 (concluded by T3). In Step 3, participants received maintenance treatments for 6 months (concluded by T4). At 24 months after baseline (T5), we performed follow-up assessments. The primary endpoint was child ADHD/ODD score (observer blind rating). Outcomes at T5 were evaluated using ANCOVA. Assessments from 101 children and 95 mothers were available at T5. Adjusted means (m) of ADHD/ODD symptoms (range 0-26) in children did not differ between TG and CG (mean difference = 1.0; 95% CI 1.2-3.1). The maternal advantage of TG over CG on the CAARS-O:L ADHD index (range 0-36) disappeared at T5 (mean difference = 0.2; 95% CI - 2.3 to 2.6). Sensitivity analyses controlling for medication and significant predictors of follow-up participation showed unchanged outcomes. Within-group outcomes remained improved from baseline. At the 24-month follow-up, TG and CG converged. The superiority of intensive treatment regarding maternal symptoms disappeared. In general, cross-generational treatment seems to be effective in the long term. (BMBF grant 01GV0605; registration ISRCTN73911400).

Entities:  

Keywords:  Cross-generational ADHD treatment; Follow-up; Maternal ADHD; Methylphenidate; Multiplex families; Parent child training

Year:  2019        PMID: 31807943     DOI: 10.1007/s00787-019-01451-0

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  56 in total

1.  Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale.

Authors:  Ronald C Kessler; Jennifer Greif Green; Lenard A Adler; Russell A Barkley; Somnath Chatterji; Stephen V Faraone; Matthew Finkelman; Laurence L Greenhill; Michael J Gruber; Mark Jewell; Leo J Russo; Nancy A Sampson; David L Van Brunt
Journal:  Arch Gen Psychiatry       Date:  2010-11

Review 2.  Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains.

Authors:  David Daley; Saskia van der Oord; Maite Ferrin; Marina Danckaerts; Manfred Doepfner; Samuele Cortese; Edmund J S Sonuga-Barke
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-06-26       Impact factor: 8.829

Review 3.  Molecular genetics of attention-deficit/hyperactivity disorder.

Authors:  Stephen V Faraone; Roy H Perlis; Alysa E Doyle; Jordan W Smoller; Jennifer J Goralnick; Meredith A Holmgren; Pamela Sklar
Journal:  Biol Psychiatry       Date:  2005-01-21       Impact factor: 13.382

Review 4.  [The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness].

Authors:  M Schlander; G-E Trott; O Schwarz
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

5.  Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

Authors:  J Biederman; E Mick; S V Faraone
Journal:  Am J Psychiatry       Date:  2000-05       Impact factor: 18.112

Review 6.  Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle.

Authors:  T Spencer; J Biederman; T Wilens; M Harding; D O'Donnell; S Griffin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-04       Impact factor: 8.829

7.  Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Guilherme Polanczyk; Cristian Zeni; Julia P Genro; Ana P Guimarães; Tatiana Roman; Mara H Hutz; Luis A Rohde
Journal:  Arch Gen Psychiatry       Date:  2007-02

8.  Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records.

Authors:  Salvatore Mannuzza; Rachel G Klein; John L Moulton
Journal:  Psychiatry Res       Date:  2008-08-15       Impact factor: 3.222

9.  A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder.

Authors:  Gregory A Fabiano; William E Pelham; Erika K Coles; Elizabeth M Gnagy; Andrea Chronis-Tuscano; Briannon C O'Connor
Journal:  Clin Psychol Rev       Date:  2008-11-11

Review 10.  Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder.

Authors:  David R Coghill; Tobias Banaschewski; César Soutullo; Matthew G Cottingham; Alessandro Zuddas
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-04-20       Impact factor: 4.785

View more
  1 in total

Review 1.  Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Kim Boesen; Asger Sand Paludan-Müller; Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.